Quidel Corp
Ouvert
10.95 -13.1
Résumé
Variation du prix de l'action
24h
Min
10.14
Max
12.6
Revenu | 602M -131M |
|---|---|
Ventes | 24M 724M |
Marge bénéficiaire | -18.062 |
Employés | 6,500 |
Recommandations | Neutre |
|---|---|
Prévisions sur 12 Mois | +66.43% upside |
Capitalisation Boursière | -509M 700M |
|---|---|
Ouverture précédente | 24.05 |
Clôture précédente | 10.95 |
Quidel Corp Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Quidel Corp prévision
Objectif de Prix
By TipRanks
66.43% hausse
Prévisions sur 12 Mois
Moyen 20.67 USD 66.43%
Haut 30 USD
Bas 15 USD
Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
Frais Généraux et Administratifs
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
Bénéfice d'exploitation
$
À Propos Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
